The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCraven House Capital Regulatory News (CRV)

Share Price Information for Craven House Capital (CRV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.20
Bid: 0.15
Ask: 0.25
Change: 0.00 (0.00%)
Spread: 0.10 (66.667%)
Open: 0.20
High: 0.20
Low: 0.20
Prev. Close: 0.20
CRV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investee Company Update: YRRO Ltd

9 Dec 2020 07:00

RNS Number : 9932H
Craven House Capital PLC
09 December 2020
 

Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR"). Upon publication of this Announcement, this information is now considered to be in the public domain.

 

Craven House Capital plc

Investee Company Update: YRRO Ltd

Craven House Capital plc ("Craven" or the "Company"), the AIM quoted investment company, is pleased to reproduce the following announcement issued today by Black Sea Property AS ("BSP"), with regards to it entering into an option agreement to acquire certain business assets from YRRO Ltd ("Yrro"), an investee company specialising in the distribution and sale of dietary supplements, in which Craven has a 29.99% stake in.

For the six month period to 31 January 2020, YRRO, which was incorporated in July 2019, showed a loss of £25,883 and a net asset value at 31 January 2020 of £53,678.

"Black Sea Property as: Enters into option agreement to acquire Omega 3 and Collagen business

Black Sea Property AS ("BSP" or the "Company") hereby announces that it has entered into an option agreement (the "Option" and the "Option Agreement") to acquire certain business assets from YRRO Ltd ("Yrro"), a company incorporated in the UK and managed in Sweden, specialising in the distribution and sale of dietary supplements.

 

The Option provides BSP with the right, but not an obligation, to acquire at any time during the next six months the following brand names and all associated rights, including the benefit of sales, from Yrro:

 

· Omega 3, North Norway

- Omega 3 NORTH NORWAY is a 100 % Omega 3 salmon oil.

- Omega 3 NORTH NORWAY has a theme inspired by the North of Norway.

- Further information is available at www.biovitos.com

 

· Royal Norwegian Fish Oil™

- Royal Norwegian Fish Oil is a lifestyle brand of seven different Omega 3 products, with added vitamins and minerals, targeting specific lifestyle groups.

 

· Functional Omega 3

- Functional Omega 3 is a brand of 12 different Omega 3 products, also with added vitamins and minerals, focusing on different physical and mental functions.

 

· Nor Can Oil

- Yrro owns Nor Can Oil.com, a business importing and in the process of establishing sales prescription medical cannabis in Denmark. This company is applying for a licence from the Danish Medicines Agency to import, distribute and sell Omega 3 added with medical cannabis to Danish patients.

- Nor Can Oil will also sell Omega 3 with added CBD oil.

- Further information is available at: www.norcanoil.com

 

· Ocean Skin Lab

- Ocean Skin Lab is a brand of different Marine Collagen products adding vitamins, minerals

- Ocean Skin Lab will sell by subscription, as well as directly via B2B and as "private label" products

- Further information is available at www.oceanskinlab.com

 

AMAZON sales:

Yrro is a registered professional seller on all Amazon platforms and will use these platforms to accelerate its Omega 3 distribution worldwide. Yrro will list seven different Omega 3 brands on Amazon in Germany, the UK, Sweden and, subsequently, in the US.

 

Egil Melkevik, chairman of the Company, comments: "In a time with significant uncertainty in the global tourism markets, this Option provides the Company and its shareholders with a potential for additional value creation and diversification of its investment in Black Sea Property. We look forward to following the development of Yrro in the coming six months, while continuing our work with the development of the Sunrise Gardens Hotel".

 

Cato Crogh, CEO of Yrro, comments: "As CEO and founder of Yrro, I see the potential transaction with Black Sea Property as strategically important for Yrro, and I am confident that it can offer the potential for a great boost in organic growth for our Omega 3 and health business. Going forward, we shall also look into opportunities for growth through acquisition, both in established and new markets for our product segment."

 

Under the terms of the Option Agreement, the purchase price for the assets will be NOK 130,000,000. The consideration payable upon exercise of the Option is to be settled by the issuance of new consideration shares in BSP to the shareholders of Yrro, whereby the shareholders of Yrro will receive an amount of shares in the Company corresponding to 85% of the outstanding shares in the Company following the Option exercise. The existing shareholders of BSP will consequently hold 15% of the shares in the combined company.

 

No option premium is payable by BSP for entering into the Option Agreement with the shareholders of Yrro. The Option may be exercised at the sole discretion of BSP. During the option period of six months, BSP will carry out a customary due diligence review to assess the benefits of exercising the Option. The consummation of any acquisition of business assets following exercise of the Option will be subject to, inter alia, the parties entering into a definitive agreement; and to approval by the shareholders of the Company for the issuance of the consideration shares.

 

If the Option is exercised, the current activities of the Company (i.e., ownership and development of the Sunrise Gardens Hotel in Aheloy, Bulgaria) will be divested into a new corporate entity."

 

Further announcements will be made in due course.

 

 

~ Ends ~

For further information please contact:

Craven House Capital Plc

Mark Pajak

www.Cravenhousecapital.com

 

Tel: 0203 286 8130

 

 

SI Capital

Broker

Nick Emerson

www.sicapital.co.uk

Tel: 01483 413500

 

SPARK Advisory Partners Limited

Nominated Adviser

Matt Davis/James Keeshan

www.Sparkadvisorypartners.com

 

 

Tel: 0203 368 3550

 

 

About Craven House Capital:

 The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFFFVFFLLTIII
Date   Source Headline
2nd Mar 20104:45 pmPRNAnnual Financial Report
26th Feb 20102:38 pmRNSInterim Results
18th Feb 20107:00 amPRNRe Agreement Investment Advisory
8th Feb 20104:46 pmRNSDirectorate Change
29th Jan 20102:34 pmRNSTotal Voting Rights
13th Jan 20103:43 pmRNSHolding(s) in Company
29th Dec 200911:43 amRNSInvesting Policy
22nd Oct 20097:00 amRNSDirectorate Change
16th Oct 20092:30 pmRNSCapitalisation of Loan
6th Oct 20094:57 pmRNSHolding(s) in Company
5th Oct 20092:45 pmRNSDirectors' Shareholding
28th Sep 200911:26 amRNSDirector Resignation
14th Sep 20094:39 pmPRNHalf-yearly Report
11th Sep 20093:39 pmRNSDirectorate Change
11th Sep 20093:26 pmRNSAGM Statement
31st Jul 200911:51 amRNSNotice of AGM
31st Jul 20097:00 amRNSAnnual Report
2nd Jun 200910:30 amRNSHoldings in Company
29th May 20094:04 pmRNSDirector Shareholding
26th May 20091:15 pmRNSChange of Adviser
20th May 20094:50 pmRNSDirector/PDMR Shareholding
20th May 20094:47 pmRNSre: Sub-Division of Shares
20th May 20097:00 amRNSDirectorate Change
15th May 20092:31 pmRNSTrading Statement
13th May 20099:43 amPRNIncrease in Performance Fees
11th May 20097:00 amRNSRestoration - Medsea Estates Group plc
8th May 20095:15 pmRNSChange of Adviser
30th Apr 20092:37 pmRNSResult of EGM
27th Apr 200911:44 amRNSAddendum and Appt of Director
22nd Apr 200910:30 amRNSDirectorate Change
6th Apr 200912:10 pmRNSResignation of Nomad and Broker
6th Apr 200912:10 pmRNSSuspension - Medsea Estates Group plc
19th Mar 20093:48 pmRNSTrading Update- Replacement
19th Mar 200911:45 amRNSTrading Update
1st Dec 200810:20 amRNSDirectorate Change
10th Nov 200810:45 amRNSUpdate re proposed delisting
30th Sep 20084:17 pmRNSTotal Voting Rights
30th Sep 20087:00 amRNSInterim Results
8th Sep 200811:00 amRNSProposed cancellation of AIM
4th Sep 200811:37 amRNSResult of AGM
1st Sep 20083:06 pmRNSDirectorate Change
13th Aug 20089:17 amRNSNotice of AGM
4th Jul 200810:47 amRNSDirector/PDMR Shareholding
30th Jun 20084:00 pmRNSAnnual Report and Accounts
30th Jun 20087:00 amRNSFinal Results
30th Apr 200811:03 amRNSUpdate re Report & Accounts
18th Feb 20083:00 pmRNSDirector/PDMR Shareholding
13th Feb 20083:04 pmRNSTrading Statement
23rd Nov 20077:01 amRNSDirectorate Change
28th Sep 20077:05 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.